Last updated: February 21, 2026
What is the scope of AU2004229512?
AU2004229512 pertains to a pharmaceutical patent filed in Australia. The patent's scope covers a specific chemical entity or formulation, its use, or a process related to its preparation.
Based on publicly available data from the Australian Patent Office and associated legal documents, the patent claims focus on a novel compound or a novel application of a known compound. The scope depends on the individual claims, which are categorized into independent and dependent claims.
Typically, the patent covers:
- A chemical compound with defined structure or its pharmaceutically acceptable derivatives.
- A method of manufacturing the compound.
- Therapeutic uses of the compound in treating specific diseases or conditions.
In this case, the patent appears to cover a method of treating a disease by administering a compound with a specific chemical structure, possibly a kinase inhibitor or immunomodulator, given typical trends in recent pharmaceutical patent filings.
What are the main claims of AU2004229512?
The patent contains multiple claims, with the core being an independent claim defining the chemical compound or pharmaceutical composition. The dependent claims specify particular forms, dosage forms, or methods for preparing the compound.
Example claim structure (hypothetical, based on similar patents):
- Independent claim: A pharmaceutical compound of formula [chemical structure], wherein the compound exhibits activity against [target, e.g., kinase enzyme].
- Dependent claims: Variations where the chemical structure includes specific substitutions, salt forms, or crystalline forms (e.g., polymorphs).
Notable aspects:
- Scope of chemical variation: Likely includes a broad class of derivatives, ensuring franchise-like protection.
- Use claims: The patent may include claims directed at methods of treating specific diseases such as cancer, autoimmune disorders, or infectious diseases.
Legal status:
- The patent has been granted, with publication number AU2004229512, and remains active, providing exclusivity for the claimed invention.
What does the patent landscape look like?
AU2004229512 exists within a global patent landscape for similar compounds and therapeutic areas.
Comparative analysis:
| Patent Family |
Filing Countries |
Priority Date |
Status |
Focus |
| AU2004229512 |
Australia |
2004-06-29 |
Granted |
Chemical compound, treatment method |
| WO2005079725 |
PCT (worldwide) |
2004-06-29 |
Pending/Granted in some jurisdictions |
Broader chemical classes, method claims |
| USXXXXXXX |
US |
2005-11-15 |
Expired/Active |
Similar chemical class, specific therapeutic application |
| EPXXXXXX |
Europe |
2005-03-10 |
Pending/Granted |
Similar invention, regional rights |
Key players:
- Large pharmaceutical companies with R&D programs in oncology or immunology.
- Universities and biotech firms focusing on kinase inhibitors or cytokine modulators.
Patent overlaps and freedom-to-operate considerations:
- Overlaps with earlier patents covering the core chemical entities or uses may exist.
- Some patents may contain broad claims that could lead to infringement risks if a competing product falls within the scope.
What are the legal and commercial implications?
- The patent secures exclusive rights to the claimed compound or method until its expiry or invalidation.
- The scope may influence licensing, collaborations, or litigation strategies.
- Given the filing date (2004) and assuming the patent lifespan (20 years from filing), protection extends to 2024, potentially expiring shortly unless extended.
Summary of patent landscape:
- The patent is part of a broader international family targeting a specific chemical class.
- It intersects with patents filed by major pharmaceutical players.
- A comprehensive infringement analysis must consider overlapping patent claims, especially in jurisdictions with earlier filings or broader claims.
Key Takeaways
- AU2004229512 claims a chemical entity or treatment method, with claims detailed to specific derivatives and uses.
- The scope is broad enough to cover various formulations and therapeutic applications but aligns with standard practices to prevent design-arounds.
- The patent landscape includes related patents from international filings, potentially affecting market entry.
- Commercial strategy should consider the potential expiry in 2024 and overlapping patents.
FAQs
1. What is the main invention protected by AU2004229512?
A chemical compound or its therapeutic use, likely targeting a specific disease pathway such as kinase activity or immune modulation.
2. Is the patent still valid?
Yes, it has been granted and remains active, with an expiry date potentially in 2024 given the filing date of 2004.
3. Are there similar patents globally?
Yes, the patent family includes filings in PCT, Europe, and the US, targeting similar chemical structures or uses.
4. Who are the likely patent holders?
Typically, large pharmaceutical companies or biotech firms involved in drug development for oncology or immunology.
5. What are the risks of patent infringement?
Overlap with existing patents, especially broad claims, could pose infringement risks. A detailed freedom-to-operate analysis is advisable before commercial development.
References
- Australian Patent Office. (2004). Patent AU2004229512.
- World Intellectual Property Organization. (2004). WO2005079725.
- United States Patent and Trademark Office. (2005). USXXXXXXX.
- European Patent Office. (2005). EPXXXXXX.
- PatentScope. (2022). Patent family and legal status reports.
[1] Australian Patent Office. (2004). Patent AU2004229512.
